Selinexor and Backbone Treatments of Multiple Myeloma Patients

ClinicalTrials.gov ID: NCT02343042

Public ClinicalTrials.gov record NCT02343042. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 4, 2026, 6:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are: * Arm 1: Selinexor + dexamethasone + pomalidomide (SPd); enrollment complete * Arm 2: Selinexor + dexamethasone + bortezomib (SVd); enrollment complete * Arm 3: Selinexor + dexamethasone + lenalidomide (SRd) in RRMM; enrollment complete * Arm 4: Selinexor + dexamethasone + pomalidomide + bortezomib (SPVd); enrollment complete * Arm 5: Selinexor + dexamethasone + daratumumab (SDd); enrollment complete * Arm 6: Selinexor + dexamethasone + carfilzomib (SKd); enrollment complete * Arm 7: Selinexor + dexamethasone + lenalidomide (SRd) in NDMM; enrollment complete * Arm 8: Selinexor + dexamethasone + ixazomib (SNd); enrollment complete * Arm 9: Selinexor + dexamethasone + pomalidomide + elotuzumab (SPEd); enrollment complete * Arm 10: Selinexor + dexamethasone + belantamab mafodotin (SBd); enrollment complete * Arm 11: Selinexor + dexamethasone + pomalidomide + daratumumab (SDPd); enrollment complete * Arm 12: Selinexor + dexamethasone + mezigdomide (SMd); actively recruiting Selinexor pharmacokinetics: * PK Run-in (Days 1-14): Starting in protocol version 8.0, patients enrolled to any arm in the Dose Escalation Phase (i.e., Arm 4 \[SPVd\], Arm 6 \[SKd\], Arm 8 \[SNd\], Arm 9 \[SPEd\], Arm 10 \[SBd\], and Arm 11 \[SDPd\]) will also first be enrolled to a pharmacokinetics (PK) Run-in period until 9 patients have been enrolled to this period to evaluate the PK of selinexor before and after co-administration with a strong CYP3A4 inhibitor. This run-in period does not apply to Arm 12 (SMd).

Study identification

NCT ID: NCT02343042
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Enrollment: 300 participants

Conditions and interventions

Conditions

Multiple Myeloma

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 30, 2015
Primary completion: Mar 31, 2027
Completion: Mar 31, 2027
Last update posted: Jul 14, 2026

2015 – 2027

United States locations

U.S. sites: 16
U.S. states: 11
U.S. cities: 13

Facility	City	State	ZIP	Site status
Banner MD Anderson Cancer Center	Gilbert	Arizona	85234	Active, not recruiting
Jonnsson Comprehensive Cancer Center / University of Los Angeles	Los Angeles	California	0095	Active, not recruiting
Sarah Cannon-Colorado Blood Cancer Institute	Denver	Colorado	80218	Withdrawn
Massachusetts General Hospital	Boston	Massachusetts	02114	Completed
Dana Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
University of Nebraska Medical Center	Omaha	Nebraska	68198	Completed
Hackensack University Medical Center - John Theurer Cancer Center	Hackensack	New Jersey	07601	Active, not recruiting
Columbia University	New York	New York	10032	Completed
Weill Cornell Medicine	New York	New York	10065	Completed
Wilmot Cancer Center/ University of Rochester	Rochester	New York	—	Active, not recruiting
University of North Carolina - Chapel Hill Comprehensive Cancer Center	Chapel Hill	North Carolina	27599	Active, not recruiting
Duke Institute of Cancer/ Duke University	Durham	North Carolina	27710	Recruiting
Sarah Cannon- Tennessee Oncology Nashville	Nashville	Tennessee	37203	Active, not recruiting
Fred Hutch Cancer Center	Seattle	Washington	98109	Recruiting
Swedish Cancer Institute	Seattle	Washington	98109	Completed
University of Wisconsin School of Medicine and Public Health	Madison	Wisconsin	53792	Active, not recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02343042, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 14, 2026 · Synced Sep 4, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02343042 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →